Hadar Goldvaser

11PUBLICATIONS

16CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsEpidemiological methodsMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|Jun 26, 2026

A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer.

|Nov 19, 2024

ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.

Hadar Goldvaser, Rinat Yerushalmi, Raz Mutai

|Feb 12, 2024

The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.

Raz Mutai, Iryna Kuchuk, Alexandra Goldshtein

|Mar 21, 2021

Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.

Michal Sternschuss, Rinat Yerushalmi, Ramy R Saleh

|Feb 12, 2021

Incidence of lung cancer following pneumonia in smokers: a population-based study.

D Shepshelovich, N Barda, H Goldvaser

|Sep 02, 2020

Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.

Yulia Kundel, Michal Sternschuss, Assaf Moore

Pageof 2

Frequent Collaborators

Assaf Moore

D Shepshelovich

T Diker-Cohen

Eitan Amir

Daniel A Goldstein

Alberto A Gabizon

Adar Yaacov

Ora S Rosengarten

Nathan Cherny

Rut Isacson

Frequent Collaborators

Assaf Moore

D Shepshelovich

T Diker-Cohen

Eitan Amir